胶质瘤
免疫疗法
接种疫苗
离体
CD8型
医学
免疫系统
白细胞介素2受体
癌症研究
免疫学
细胞毒性T细胞
体内
免疫
脾脏
T细胞
生物
体外
生物技术
生物化学
作者
Wim Maes,Georgina Galicia,Bert Verbinnen,Louis Boon,Steven De Vleeschouwer,Jan Ceuppens,Stefaan Van Gool
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2009-03-31
卷期号:11 (5): 529-542
被引量:105
标识
DOI:10.1215/15228517-2009-004
摘要
We studied the feasibility, efficacy, and mechanisms of dendritic cell (DC) immunotherapy against murine malignant glioma in the experimental GL261 intracranial (IC) tumor model. When administered prophylactically, mature DCs (DCm) ex vivo loaded with GL261 RNA (DCm-GL261-RNA) protected half of the vaccinated mice against IC glioma, whereas treatment with mock-loaded DCm or DCm loaded with irrelevant antigens did not result in tumor protection. In DCm-GL261-RNA-vaccinated mice, a tumor-specific cellular immune response was observed ex vivo in the spleen and tumordraining lymph node cells. Specificity was also shown in vivo on the level of tumor challenge. Depletion of CD8(+) T-cells by anti-CD8 treatment at the time of tumor challenge demonstrated their essential role in vaccine-mediated antitumor immunity. Depletion of CD25(+) regulatory T-cells (Tregs) by anti-CD25 (aCD25) treatment strongly enhanced the efficacy of DC vaccination and was itself also protective, independently of DC vaccination. However, DC vaccination was essential to protect the animals from IC tumor rechallenge. No long-term protection was observed in animals that initially received aCD25 treatment only. In mice that received DC and/or aCD25 treatment, we retrieved tumor-specific brain-infiltrating cytotoxic T-lymphocytes. These data clearly demonstrate the effectiveness of DC vaccination for the induction of long-lasting immunological protection against IC glioma. They also show the beneficial effect of Treg depletion in this kind of glioma immunotherapy, even combined with DC vaccination.
科研通智能强力驱动
Strongly Powered by AbleSci AI